Registry of pulmonary hypertension in Poland
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
This study is tracking patients with pulmonary hypertension in Poland to see how their condition is managed and what outcomes they experience.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 3 Months and up |
| Sex | All |
| Sponsor | Polish Cardiology Association Academic / other |
| Locations | 1 site (Krakow) |
| Trial ID | NCT03959748 on ClinicalTrials.gov |
What this trial studies
The BNP-PL is a multicenter, observational registry that follows patients diagnosed with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Poland. It aims to investigate the clinical course and management of these conditions by collecting data from accredited pulmonary hypertension centers across the country. The data is managed by Jagiellonian University Medical College and focuses on describing current practices and outcomes without impacting patient diagnosis or treatment. Data collection is conducted through an electronic platform, ensuring patient confidentiality.
Who should consider this trial
Good fit: Ideal candidates include patients aged over 3 months diagnosed with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension after March 1, 2018.
Not a fit: Patients diagnosed with pulmonary hypertension before March 1, 2018, may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of pulmonary hypertension management and improve patient outcomes in Poland.
How similar studies have performed: Other observational registries in pulmonary hypertension have shown success in improving patient management and outcomes, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension diagnosed after 1st March 2018 (incident cases) who: * are aged \> 3 months at the time of enrollment * fulfill the following hemodinamic criteria: mean pulmonary arterial pressure (mPAP) of 25 mm Hg or more, mean pulmonary arterial wedge pressure (PAWP) or left ventricular end-diastolic pressure (PVEDP) of 15 mm Hg or less, pulmonary vascular resistance (PVR) of 3 Woods. Patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension diagnosed before 1st March 2018 (prevalent cases) who: * are aged \> 3 months at the time of enrollment * fulfill the following hemodinamic criteria: mean pulmonary arterial pressure (mPAP) of 25 mm Hg or more, mean pulmonary arterial wedge pressure (PAWP) or left ventricular end-diastolic pressure (PVEDP) of 15 mm Hg or less, pulmonary vascular resistance (PVR) of 3 Woods
Where this trial is running
Krakow
- Krakowski Szpital Specjalistyczny im. Jana Pawła II — Krakow, Poland (Recruiting)
Study contacts
- Principal investigator: Grzegorz Kopeć, MD, Phd — Krakowski Szpital Specjalistyczny im. Jana Pawła II
- Study coordinator: Grzegorz Kopeć
- Email: grzegorzkrakow1@gmail.com
- Phone: +48 12 614 33 99
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.